Altimmune (NASDAQ:ALT) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

A number of other brokerages have also weighed in on ALT. Stifel Nicolaus began coverage on Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective on the stock. UBS Group initiated coverage on shares of Altimmune in a research report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $20.83.

Altimmune Stock Down 3.6 %

ALT opened at $6.66 on Wednesday. The company has a market cap of $473.69 million, a PE ratio of -4.30 and a beta of 0.19. Altimmune has a twelve month low of $5.28 and a twelve month high of $14.84. The company has a 50-day moving average price of $7.59 and a 200 day moving average price of $7.17.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the firm posted ($0.39) earnings per share. As a group, sell-side analysts expect that Altimmune will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

Hedge funds have recently modified their holdings of the company. Sequoia Financial Advisors LLC raised its stake in Altimmune by 34.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock worth $98,000 after purchasing an additional 3,500 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $88,000. Cullen Frost Bankers Inc. purchased a new stake in shares of Altimmune during the 4th quarter valued at approximately $72,000. Steward Partners Investment Advisory LLC lifted its holdings in Altimmune by 38.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 28,050 shares of the company’s stock valued at $202,000 after acquiring an additional 7,850 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in Altimmune in the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.